PubMed Health⌕ Search

Biomedical subjects

Dan Guo

Publications and source records attributed to Dan Guo.

12 recordsLinked to original sources

G-quadruplex upstream of PAX9 TSS acts as a 3D-genome scaffold to remotely silence X-linked genes and modulate cell-cycle progression.

G-quadruplexes (G4s) are non-canonical DNA secondary structures that act as local replication barriers and transcriptional regulators. Whether G4 can simultaneously influence splicing, DNA replication, and long-range, trans-chromosomal gene regulation remains untested. Here we combined in vitro biophysics, CRISPR mutagenesis and multi-omics to dissect a conserved G4 motif (QS1) located ~173 bp upstream of the PAX9 transcription start site. CD spectroscopy confirmed that the wild-type, but not the G-to-T mutant sequence, folds into a stable parallel G4 under physiological K+. In human cells, disruption of the QS1 G4 changed chromatin accessibility, remotely down-regulated a cohort of X-linked genes, accelerated migration and delayed G1/S progression. Integrative analysis of ATAC-seq, RNA-seq profiling reveals that the QS1 G4 acts as a three-dimensional genome scaffold linking PAX9 to cell-cycle and metabolic networks. Our findings establish a pleiotropic role for a single promoter G4 in coordinating DNA replication stress, chromatin architecture and trans-chromosomal transcriptional control.

G-Quadruplexes↗

[Effects of angiotensin II and aldosterone on NF-kappaB binding activity in hepatic stellate cells].

OBJECTIVE: To investigate the signal transduction mechanism underlying the effects of angiotensin II (AngII) and aldosterone (Aldo) on nuclear factor-kappaB (NF-kappaB) DNA binding activity. METHODS: Sixty male Wistar rats were randomly divided into 4 groups: model group (Mo group), injected with CCl(4) subcutaneously twice a week to establish a model of hepatic fibrosis; perindopril group (Pe group), injected with CCl(4) subcutaneously twice a week and perfused with perindopril once a day; losartan group (Lo group), injected with CCl(4) subcutaneously twice a week and perfused with losartan once a day; and control group (Nc group), injected with olive oil subcutaneously. The rats were killed in batches respectively 4 and 6 weeks after and their livers were collected to undergo Masson staining and be observed by light microscope. Electrophoretic gel mobility shift assay (EMSA) was used to detect the NF-kappaB DNA binding activity in the liver tissues. Western blotting was used to detect the expression of IkappaBalpha in the plasma protein. Hepatic stellate cells (HSCs)-T6 were cultured and preincubated for 1 h or not with U0126 (an inhibitor of MAPK/ERK kinase MEK), irbesartan (an AT-1 receptor blocker), and N-acetylcysteine (NAC, an antioxidant), angiotensin-converting enzyme inhibitor (ACEI), or tumor necrosis factor alpha (TNFalpha) prior to exposure to AngII or Aldo for 0.5 h, 1 h, 2 h, and 4 h respectively. The binding activities of NF-kappaB DNA were observed by EMSA. The expression of IkappaBalpha protein was detected with Western blotting. Histochemistry was used to detect the expression of NF-kappaB p65. RT-PCR was used to detect the expression of TNFalpha mRNA in HSC-T6 cells. RESULTS: The binding activity to NF-kappaB of the liver tissues was the strongest in the Mo group, followed by the Pe and Lo groups and Nc group. The IkappaBalpha expressions in liver tissues 4 and 6 weeks after the beginning of experiment in the Pe and Lo groups were significantly stronger than that in the Mo group (both P < 0.05). 0.5 hour after the intervention of AngII the DNA binding activity of the HSCs began to increase and peaked 1 hour later and then gradually decreased. The increase of NF-kappaB activity induced by AngII could be inhibited by irbesartan, ACEI and NAC pretreatment and could not be inhibited by U0126 pretreatment. Combined action of AngII and TNFalpha significantly increased the NF-kappaB DNA binding activity. The IkappaBalpha expression began to decrease 0.5 hour after the intervention of AngII and reached the lowest value 2 hours after. The expression of IkappaBalpha protein was increased by ACEI (P < 0.05), irbesartan and NAC (both P < 0.01). EMSA showed that 0.5 hour after the intervention of Aldo the DNA binding activity began to be increased and peaked by 1 hour and then began to be decreased. NAC, but not U0126 partly inhibited the increased of NF-kappaB activity induced by Aldo. Combined action of Aldo and TNFalpha significantly increased the NF-kappaB activity. Aldo increased the expression of IkappaBalpha protein in the HSCs at different time points (all P < 0.05). 0.5 hour after the AngII intervention the IkappaBalpha protein expression began to decrease and reach the lowest value 1 hour later and then began to increase 2 hours later. the IkappaBalpha protein expression was significantly decreased in the NAC and NAC+ Aldo intervention groups (both P < 0.05). There was no significant difference in IkappaBalpha protein expression between the Aldo intervention group and U0126 + Aldo, TNFalpha, and Aldo + TNFalpha treatment groups (all P > 0.05). Before stimulation, NF-kappaB was expressed in the plasma of HSCs, however, after the stimulation of AngII or Aldo for 1 hour it was expressed in the nuclei, and then transferred from the nuclei to the plasma 4 hours after the stimulation. However, little nuclear transfer was observed after pretreatment of NAC followed by AngII or Aldo intervention. The TNFalpha mRNA expression was significantly increased in the AngII and Aldo treatment groups in comparison with the control group (both P < 0.05). The TNFalpha mRNA expression was significantly weaker in the irbesartan + AngII, NAC + AngII, and ACEI groups in comparison with the AngII group (all P < 0.05). CONCLUSION: Stimulation of NF-kappaB activity mediates hepatic fibrosis induced by intrahepatic renin-angiotensin-aldosterone system (RAAS).

Aldosterone↗

RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo.

Bcl-2 is an anti-apoptotic protein. If the level of Bcl-2 protein can be reduced sufficiently in tumors using RNA interference (RNAi) to target the gene message, the apoptosis of tumor cells may be promoted. In this study, we synthesized 19 nucleotides (nts) small interference RNA (siRNA) constructs suppressing bcl-2 gene expression in human tumor cells (HeLaB2 and BGC-823 cell lines) in vitro. The bcl-2 gene expression levels were significantly reduced when these siRNA were transfected into experimental two tumor cells for 72 hours. The apoptosis process was also examined in the tumor cells. Here we synthesized siRNA from a DNA template under the control of the RNA polymerase III promoter in transfected tumor cells. Using this DNA vector-based approach, we found that the siRNA efficiently and specifically inhibited the synthesis of protein encoded by the bcl-2 gene in HeLaB2 and BGC-823 tumor cells. Tumor growth was inhibited by 66.5% with 2mg/kg pSilencer 3.1H1-bcl-2 in mouse liver tumor-bearing BALB/c mice. This approach may prove to be a valuable clinical technique for the analysis of specific gene functions and gene therapy of malignant tumors that utilize the bcl-2 gene via RNA interference.

Animals↗

[Study of biocompatibility of polybutylcyanoacrylate nanoparticles].

OBJECTIVE: To evaluate the biocompatibility of polybutylcyanoacrylate nanoparticles (PBCA-NP) manufactured by emulsion polymerization technique. METHODS: MTT assay was performed for evaluation of the cytotoxicity of PBCA-NP (e.g. cell proliferation and hemolytic test) experiments of long-term subcutaneous implantation and implantation in the muscular tissues of PBCA-NP was conducted in rabbits to observe the inflammatory reactions due to the implantation. RESULTS: No obvious cytotoxicity or hemolytic reactions were observed (with the hemolytic rate at different concentrations of PBCA-NP(5%). Three months after PBCA-NP implantation, obvious lymphocyte infiltration was not observed in the tissues around the implants which underwent gradual degradation. CONCLUSION: PBCA-NP possesses good biocompatibility.

Animals↗

[Using chamber technique for studying the permeability of dexamethasone sodium phosphate liposome through rabbit colon mucosa in vitro].

OBJECTIVE: To investigate the features of liposome-mediated drug permeability through the colon mucosa in vitro. METHODS: Dexamethasone sodium phosphate liposome (DSP) was prepared using orthogonal design. With in vitro Ussing chamber experiment, the accumulated amount of DSP permeated through rabbit colon mucosa into the receptor chamber and the distribution amount in the colon were determined at different time points during the experiment. RESULTS: Compared with the prepared DSP solution, DSP liposome decreased the permeated amount of DSP through rabbit colon mucosa. The apparent permeability coefficient (Papp, x10(-6), cm/s1) of the DSP was 31.95+/-7.65, significantly lower than that of DSP solution (88.61+/-18.61). On the other hand, the distribution amount of DSP liposome in the colon mucosa was significantly higher than that of the DSP solution both at 120 and 300 min. CONCLUSIONS: DSP liposome dosage form may induce less toxicity with better therapeutic effect in the treatment of colitis, which is worthy of further exploitation.

Animals↗

[Application of RNA interference technique in the research of mammalian cells and human disease].

RNA interference provides a new approach for elucidation of gene function. It holds the advantages of quickness, convenience, high effect and high specificity. In spite of these, the application of RNA interference technique in studying the mammalian cells and human disease is still in the beginning. In this paper, a review of the development of RNA interference in mammalian cells and human disease is presented.

Animals↗

[High-performance capillary electrophoresis for determining caffeic acid content in Fujie enema and Taraxacum mongolicum Hand.-Mazz].

OBJECTIVE: To determine caffeic acid content in Fujie enema and the crude traditional Chinese herbal drug Taraxacum mongolicum Hand.-Mazz. for controlling the quality of the enema at the levels of both the crude drugs and the final product. METHODS: Caffeic acid content in both the enema and the crude drug was determined at 313 nm Using high-performance capillary electrophoresis (HPCE), under the optimized conditions achieved with a fused-silica capillary tube (75 micromx0 cm) and 20 mmol/L borate running buffer (pH=9.18) at a constant voltage of 12 kV and a sampling time of 5 s at 25 degrees Celsius. RESULTS: The calibration curve displayed good linear relationship within caffeic acid concentration range of 10 to 100 microg/ml (r=0.999 2). The regression equation was Y=1002.45X-327.87, and the average recovery was more than 95%. CONCLUSION: HPCE is simple, rapid and sensitive in separation and determination of caffeic acid in Fujie enema and the crude drug of Taraxacum mongolicum Hand.-Mazz.

Caffeic Acids↗

[Determination of dexamethasone sodium phosphate content in Fuyankang cream by high-performance capillary electrophoresis].

OBJECTIVE: To determine the content of dexamethasone sodium phosphate in Fuyankang cream, a preparation for treatment of various skin conditions. METHODS: Dexamethasone sodium phosphate content in Fuyankang cream was determined using high-performance capillary electrophoresis (HPCE) at the detection wavelength of 254 nm, under the optimal condition achieved with a fused-silica capillary tube (60 cm x 75 microm) and 100 mmol/L sodium tetraborate buffer (pH 9.2) at a constant voltage of 25 kV with a sampling time of 10 s at 25 degrees Celsius;. RESULTS: The calibration curve displayed good linear relationship within dexamethasone sodium phosphate concentration range of 20 to 100 microg/ ml r=0.999 8 . The average recovery of dexamethasone sodium phosphate was 99.75% n=5, RSD=1.03% . CONCLUSION: HPCE is simple, quick and sensitive in determination of dexamethasone sodium phosphate content in Fuyankang cream.

Calibration↗

[Absorption and distribution of 5-aminosalicylic acid from its chitosan capsule degraded by colon bacteria-released enzymes in rats].

OBJECTIVE: To examine the absorption and distribution of 5-aminosalicylic acid (5-ASA) in rat colon after oral administration of its chitosan capsule. METHODS: 5-ASA in chitosan capsules (4.8 mg per 3 capsules) were administered orally in rats via a polyethylene cannula under light ether anesthesia. The rats in control group were given 1 ml 5-ASA carboxymethyl cellulose suspension (4.8 mg). Blood samples were obtained from the rat hearts and the colon tissues sampled at a given interval to measure the concentration of 5-ASA by HPLC. RESULTS: The area under the curve (AUC(0-12)) in the serum samples of chitosan capsule group was 0.62 times that of the control group, while in the colon tissue, the AUC(0-12) of chitosan capsule group was as much as 3.62 times that of the control group. CONCLUSION: The chitosan capsule may be a useful carrier of 5-ASA for colon-specific delivery.

Absorption↗

Experimental study of in vitro buprenorphine hydrochloride transdermal permeation through hairless mouse skin.

OBJECTIVE: To investigate the in vitro transdermal permeation of buprenorphine hydrochloride gel through hairless mouse skin and the effect of permeation enhancers on the permeability of this transdermal drug delivery system. METHODS: Skin samples 1.0 cm in diameter were obtained from hairless mice for subsequent in vitro tests of the permeability of the drug. In permeation enhancer-free group, the permeability of buprenorphine hydrochloride at the concentrations of 0.5%, 1.0% and 2.0% was tested. The permeation enhancer group (all application containing 1% buprenorphine hydrochloride) was further divided into oleic group (including 3 subgroups with 2%, 4%, and 6% oleic), azone group (subdivided into 3 groups with 1%, 2%, and 4% azone) and mixed group (with 4% oleic plus 4% azone). The permeation parameters, namely steady state flux (Js) and Js enhancement ratio were evaluated. RESULTS: Js in permeation enhancer-free groups were 0.69+/-0.11, 0.90+/-0.14 and 1.18+/-0.10 microgram/cm2.h respectively, which differed only insignificantly (P>0.05). The mixed group showed the maximum permeation, with Js and ER of 13.22+/-1.27 microgram/cm2.h and 14.6 respectively. CONCLUSION: Permeation enhancers significantly increase Js of buprenorphine hydrochloride gel and renders its release kinetics approaching zero-order.

Animals↗